WallStreetZenWallStreetZen

NYSEMKT: NSRX
Nasus Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NSRX stock forecasts and price targets.

Forecast return on equity

Is NSRX forecast to generate an efficient return?

Company
-55.4%
Industry
4.71%
Market
148.92%
NSRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NSRX forecast to generate an efficient return on assets?

Company
-48.94%
Industry
24.58%
NSRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NSRX earnings per share forecast

What is NSRX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.15
Avg 2 year Forecast
-$1.15
Avg 3 year Forecast
-$0.52

NSRX revenue forecast

What is NSRX's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$5.4M

NSRX vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
NSRX$3.92N/AN/A
SCLX$4.06N/AN/A
MIRA$0.73$3.50+379.45%Strong Buy
MDCX$0.16$9.00+5,490.06%Strong Buy
AMRN$12.35$13.00+5.26%Strong Sell
View Top General Drug Manufacturer Stocks

Nasus Pharma Stock Forecast FAQ

What is NSRX's earnings growth forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 53.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.82%.

Nasus Pharma's earnings in 2026 is -$10,546,000.On average, 5 Wall Street analysts forecast NSRX's earnings for 2026 to be -$13,486,166, with the lowest NSRX earnings forecast at -$14,656,076, and the highest NSRX earnings forecast at -$10,328,933. On average, 5 Wall Street analysts forecast NSRX's earnings for 2027 to be -$13,441,665, with the lowest NSRX earnings forecast at -$16,710,152, and the highest NSRX earnings forecast at -$9,960,042.

In 2028, NSRX is forecast to generate -$6,091,962 in earnings, with the lowest earnings forecast at -$7,459,785 and the highest earnings forecast at -$4,549,649.

If you're new to stock investing, here's how to buy Nasus Pharma stock.

What is NSRX's revenue growth forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.2%.

Nasus Pharma's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast NSRX's revenue for 2026 to be $0, with the lowest NSRX revenue forecast at $0, and the highest NSRX revenue forecast at $0. On average, 5 Wall Street analysts forecast NSRX's revenue for 2027 to be $0, with the lowest NSRX revenue forecast at $0, and the highest NSRX revenue forecast at $0.

In 2028, NSRX is forecast to generate $63,261,785 in revenue, with the lowest revenue forecast at $39,512,266 and the highest revenue forecast at $87,924,746.

What is NSRX's forecast return on assets (ROA) for 2026-2028?

(NYSEMKT: NSRX) forecast ROA is -48.94%, which is lower than the forecast US Drug Manufacturers - General industry average of 24.58%.

What is NSRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: NSRX) Nasus Pharma's current Earnings Per Share (EPS) is -$1.09. On average, analysts forecast that NSRX's EPS will be -$1.15 for 2026, with the lowest EPS forecast at -$1.25, and the highest EPS forecast at -$0.88. On average, analysts forecast that NSRX's EPS will be -$1.15 for 2027, with the lowest EPS forecast at -$1.43, and the highest EPS forecast at -$0.85. In 2028, NSRX's EPS is forecast to hit -$0.52 (min: -$0.64, max: -$0.39).

What is NSRX's forecast return on equity (ROE) for 2026-2028?

(NYSEMKT: NSRX) forecast ROE is -55.4%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.